Amikacin liposome inhalation suspension clinical benefit–risk assessment for refractory Mycobacterium avium complex lung disease
Theodore K. Marras, Mariam Hassan, Kevin C. Mange, Monika Ciesielska, Shilpa Dhar Murthy, Zhanna Jumadilova, Anjan Chatterjee
Source: ERJ Open Res, 8 (3) 00623-2021; 10.1183/23120541.00623-2021
  
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Theodore K. Marras, Mariam Hassan, Kevin C. Mange, Monika Ciesielska, Shilpa Dhar Murthy, Zhanna Jumadilova, Anjan Chatterjee. Amikacin liposome inhalation suspension clinical benefit–risk assessment for refractory Mycobacterium avium complex lung disease. ERJ Open Res, 8 (3) 00623-2021; 10.1183/23120541.00623-2021
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|